AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Inogen, Inc.
Video analysis: INGN
All videosNo video analysis for this stock yet. Request one from our team.
News: INGN
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Dimensional Fund Advisors LP Reduces Position in Inogen, Inc $INGN
Dimensional Fund Advisors LP decreased its holdings in Inogen, Inc (NASDAQ: INGN) by 28.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 509,822 shares of the medical technology company's stock after selling 201,558 shares during the period. Dimensional Fund
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen Q2 Earnings Call Highlights
Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
